GlassScriptPhysician profile
Louis Brenner
NPI 1003852815
$3,554.61
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $348 · 2021: $1,112 · 2022: $753.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $679.64 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $361.59 | 2019-2022 | |
| Lilly USA, LLC | $345.75 | 2019-2022 | |
| Pfizer INC. | $328.61 | 2019-2021 | |
| Glaxosmithkline, LLC. | $304.80 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.09 | 2019-2022 | |
| Novo Nordisk INC | $190.80 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $109.00 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $99.48 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $97.46 | 2019-2021 | |
| Sanofi Pasteur INC. | $94.00 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $93.81 | 2019-2021 | |
| Amgen INC. | $93.71 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $83.37 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.90 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $75.15 | 2022 | |
| Amarin Pharma, INC. | $50.93 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $41.77 | 2021 | |
| Allergan, INC. | $31.07 | 2019-2020 | |
| Boston Scientific Corporation | $26.18 | 2019 | |
| Eisai INC. | $23.03 | 2022 | |
| Astellas Pharma US INC | $21.33 | 2019 | |
| Abbott Laboratories | $19.18 | 2022 | |
| Aytu Biopharma, INC. | $16.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.63 | 2019 | |
| Esperion Therapeutics, INC. | $13.20 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Brenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.